Blue Cross plans to target doctors for overcharging. Physicians are furious (STAT)
Cigna says it will move to end drug rebates beginning in 2027 (Endpoints)
UnitedHealth Sees 2026 Growth as It Navigates Historic Meltdown (Bloomberg)
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks (Reuters)
Onshoring Drug Manufacturing: Insights from FDA’s PreCheck Initiative and Public Meeting (FDA Law Blog)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
The US Food and Drug Administration’s (FDA) Office of Translational Sciences (OTS) and the Office of Clinical Pharmacology (OCP) recently released a new manual of procedures and policies (MAPP) which outlines the good review practices (GRPs) for the clinical pharmacology review of new drug applications (NDAs) and biologics license applications (BLAs). Both offices operate under FDA’s Center for Drug Evaluation and Research (CDER).
BALTIMORE – A panel of European regulators and industry representatives discussed how to streamline the regulatory process for combination products in the European Union at the AFDO/RAPS Combination Products Summit.
The US Food and Drug Administration (FDA) announced that, as of Monday, it will use the term “super intelligence” instead of “artificial intelligence” in all official correspondence, public communications, websites, reports, and policy documents.